Rational modification of oligoarginine for highly efficient siRNA delivery: Structure-activity relationship and mechanism of intracellular trafficking of siRNA

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 435-446

  Chu, Dafeng ^a   Xu, Wen ^a   Pan, Ran ^a   Ding, Yong ^a   Sui, Weiping ^a   Chen, P ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Endosomal escape; Gene silencing; Nanoparticle; Peptide; SiRNA delivery

Indexed keywords

AMINO ACIDS; EFFICIENCY; GENES; GENETIC ENGINEERING; NANOPARTICLES; PEPTIDES;

CELL PENETRATING PEPTIDES (CPPS); ENDOSOMAL ESCAPES; GENE SILENCING; INTRACELLULAR TRAFFICKING; PEPTIDE SEQUENCES; SIRNA DELIVERY; STRUCTURE ACTIVITY RELATIONSHIPS; THERAPEUTIC MOLECULES;

RNA;

ARGININE; CELL PENETRATING PEPTIDE; HISTIDINE; NANOPARTICLE; OLIGOARGININE; OLIGOHISTIDINE; RIBONUCLEASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATOMIC FORCE MICROSCOPY; CHO CELL LINE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG UPTAKE; ENDOSOME; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELIVERY SYSTEM; GENE SILENCING; HELA CELL LINE; NONHUMAN; PARTICLE SIZE; STRUCTURE ACTIVITY RELATION; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; CRICETULUS; GENE TRANSFER; GENETICS; HUMAN;

ANIMALS; ARGININE; CELL-PENETRATING PEPTIDES; CHO CELLS; CRICETULUS; ENDOSOMES; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; HUMANS; MICROSCOPY, ATOMIC FORCE; NANOPARTICLES; PARTICLE SIZE; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922765691     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.08.007     Document Type: Article

References (49)

1. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
2. Shen H., Sun T., Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012, 19:367-373.
3. Devi G.R. siRNA-based approaches in cancer therapy. Cancer Gene Ther 2006, 13:819-829.
4. Laufer S.D., Detzer A., Sczakiel G., Restle T. Selected strategies for the delivery of siRNA in vitro and in vivo. RNA technologies and their applications 2010, 29-58. Springer, Berlin, Heidelberg. V.A. Erdmann, J. Barciszewski (Eds.).
5. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
6. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
7. Allerson C.R., Sioufi N., Jarres R., Prakash T.P., Naik N., Berdeja A., et al. Fully 2 '-modified oligonucleotide duplexes with improved in vitro unmodified small interfering RNA. J Med Chem 2005, 48:901-904.
8. Dominska M., Dykxhoorn D.M. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010, 123:1183-1189.
9. Check E. Gene therapy put on hold as third child develops cancer. Nature 2005, 433:561.
10. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
11. Kay M.A. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011, 12:316-328.
12. Rettig G.R., Behlke M.A. Progress toward in vivo use of siRNAs-II. Mol Ther 2012, 20:483-512.
13. Alabi C., Vegas A., Anderson D. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol 2012, 12:427-433.
14. Kesharwani P., Gajbhiye V., Jain N.K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33:7138-7150.
15. Zhou J., Shum K.T., Burnett J.C., Rossi J.J. Nanoparticle-based delivery of RNAi therapeutics: progress and challenges. Pharmaceuticals 2013, 6:85-107.
16. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
17. Soenen S.J.H., Brisson A.R., De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 2009, 30:3691-3701.
18. Akhtar S., Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007, 59:164-182.
19. Ballarín González B., Howard K.A. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv Drug Deliv Rev 2012, 64:1717-1729.
20. Wagstaff K.M., Jans D.A. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem 2006, 13:1371-1387.
21. Lindgren M., Langel Ü. Classes and prediction of cell-penetrating peptides. Methods Mol Biol 2011, 683:3-19.
22. Joliot A., Prochiantz A. Transduction peptides: from technology to physiology. Nat Cell Biol 2004, 6:189-196.
23. Endoh T., Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009, 61:704-709.
24. Hoyer J., Neundorf I. Peptide vectors for the nonviral delivery of nucleic acids. Acc Chem Res 2012, 45:1048-1056.
25. Lehto T., Kurrikoff K., Langel Ü. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 2012, 9:823-836.
26. Van Asbeck A.H., Beyerle A., McNeill H., Bovee-Geurts P.H.M., Lindberg S., Verdurmen W.P.R., et al. Molecular parameters of siRNA-cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano 2013, 7:3797-3807.
27. EL Andaloussi S., Lehto T., Mäger I., Rosenthal-Aizman K., Oprea I.I., Simonson O.E., et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 2011, 39:3972-3987.
28. Midoux P., Pichon C., Yaouanc J.J., Jaffrès P.A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009, 157:166-178.
29. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006, 58:32-45.
30. Li W., Nicol F., Szoka F.C. GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 2004, 56:967-985.
31. Hou K.K., Pan H., Ratner L., Schlesinger P.H., Wickline S.A. Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano 2013, 7:8605-8615.
32. Summerton J.E. Endo-porter: a novel reagent for safe, effective delivery of substances into cells. Ann N Y Acad Sci 2005, 1058:62-75.
33. Zhao Z.X., Gao S.Y., Wang J.C., Chen C.J., Zhao E.Y., Hou W.J., et al. Self-assembly nanomicelles based on cationic mPEG-PLA-B-polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials 2012, 33:6793-9807.
34. Gonçalves E., Kitas E., Seelig J. Binding of oligoarginine to membrane lipids and heparan sulfate: structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry 2005, 44:2692-2702.
35. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001, 276:5836-5840.
36. Mitchell D.J., Steinman L., Kim D.T., Fathman C.G., Rothbard J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000, 56:318-325.
37. Nakamura Y., Kogure K., Futaki S., Harashima H. Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 2007, 119:360-367.
38. Kwok A., Hart S.L. Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. Nanomedicine 2005, 7:210-219.
39. Rink J., Ghigo E., Kalaidzidis Y., Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell 2005, 122:735-749.
40. Futter C.E., Pearse A., Hewlett L.J., Hopkins C.R. Multivesicular endosomes containing internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes. J Cell Biol 1996, 132:1011-1023.
41. Luzio J.P., Rous B.A., Bright N.A., Pryor P.R., Mullock B.M., Piper R.C. Lysosome-endosome fusion and lysosome biogenesis. J Cell Sci 2000, 113:1515-1524.
42. Liang W., Lam J. Endosomal escape pathways for non-viral nucleic acid delivery systems. Molecular regulation of endocytosis 2012, 429-456. InTech, Rijeka. B. Ceresa (Ed.).
43. Bowman E.J., Siebers A., Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A 1988, 85:7972-7976.
44. Crider B.P., Xie X.S., Stone D.K. Bafilomycin inhibits proton flow through the H+channel of vacuolar proton pumps. J Biol Chem 1994, 269:17379-17381.
45. Miyata K., Oba M., Nakanishi M., Fukushima S., Yamasaki Y., Koyama H., et al. Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. J Am Chem Soc 2008, 130:16287-16294.
46. Zelphati O., Wang Y., Kitada S., Reed J.C., Felgner P.L., Corbeil J. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 2001, 276:35103-35110.
47. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010, 21:797-802.
48. Yue Y., Jin F., Deng R., Cai J., Dai Z., Lin M.C.M., et al. Revisit complexation between DNA and polyethylenimine-effect of length of free polycationic chains on gene transfection. J Control Release 2011, 152:143-151.
49. Geoghegan J.C., Gilmore B.L., Davidson B.L. Gene silencing mediated by siRNA-binding fusion proteins is attenuated by double-stranded RNA-binding domain structure. Mol Ther Acids 2012, 1:1-9.